These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29786108)

  • 1. miR‑494 inhibits cancer‑initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2‑positive gastric cancer.
    Yu Y; Yu X; Liu H; Song Q; Yang Y
    Int J Mol Med; 2018 Aug; 42(2):998-1007. PubMed ID: 29786108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
    Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
    Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
    Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
    Azuma K; Tsurutani J; Sakai K; Kaneda H; Fujisaka Y; Takeda M; Watatani M; Arao T; Satoh T; Okamoto I; Kurata T; Nishio K; Nakagawa K
    Biochem Biophys Res Commun; 2011 Apr; 407(1):219-24. PubMed ID: 21377448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
    Park J; Choi Y; Ko YS; Kim Y; Pyo JS; Jang BG; Kim MA; Lee JS; Chang MS; Park JW; Lee BL
    Cancer Res Treat; 2018 Jan; 50(1):239-254. PubMed ID: 28343375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
    Venturutti L; Cordo Russo RI; Rivas MA; Mercogliano MF; Izzo F; Oakley RH; Pereyra MG; De Martino M; Proietti CJ; Yankilevich P; Roa JC; Guzmán P; Cortese E; Allemand DH; Huang TH; Charreau EH; Cidlowski JA; Schillaci R; Elizalde PV
    Oncogene; 2016 Dec; 35(48):6189-6202. PubMed ID: 27157613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
    Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
    Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
    Oshima Y; Tanaka H; Murakami H; Ito Y; Furuya T; Kondo E; Kodera Y; Nakanishi H
    Gastric Cancer; 2014; 17(3):450-62. PubMed ID: 23948998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
    Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
    Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
    Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
    Ning G; Zhu Q; Kang W; Lee H; Maher L; Suh YS; Michaud M; Silva M; Kwon JY; Zhang C; Lee C
    BMC Cancer; 2021 Aug; 21(1):923. PubMed ID: 34399705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
    Takeda M; Arao T; Yokote H; Komatsu T; Yanagihara K; Sasaki H; Yamada Y; Tamura T; Fukuoka K; Kimura H; Saijo N; Nishio K
    Clin Cancer Res; 2007 May; 13(10):3051-7. PubMed ID: 17505008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2‑positive breast cancer.
    Matsumoto A; Hayashida T; Takahashi M; Jinno H; Kitagawa Y
    Mol Med Rep; 2018 Jul; 18(1):958-964. PubMed ID: 29845287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.
    Bai M; Song N; Che X; Wang X; Qu X; Liu Y
    Cell Biol Int; 2018 Jul; 42(7):781-793. PubMed ID: 29271513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells.
    Shibata T; Kan H; Murakami Y; Ureshino H; Watari K; Kawahara A; Kage M; Hattori S; Ono M; Kuwano M
    Mol Cancer Ther; 2013 May; 12(5):737-46. PubMed ID: 23445612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
    De Silva N; Schulz L; Paterson A; Qain W; Secrier M; Godfrey E; Cheow H; O'Donovan M; Lao-Sirieix P; Jobanputra M; Hochhauser D; Fitzgerald R; Ford H
    Br J Cancer; 2015 Nov; 113(9):1305-12. PubMed ID: 26484410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
    Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
    Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells.
    Ma L; Zhu W; Wang Q; Yang F; Qian J; Xu T; Wang S; Zhou J; Shu Y
    Oncotarget; 2016 Nov; 7(44):71790-71801. PubMed ID: 27708243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.